# 遗传性血管性水肿治疗市场

> 遗传性血管性水肿治疗市场研究报告，按治疗类型（C1酯酶抑制剂替代疗法、布拉迪激肽B2受体拮抗剂、重组C1酯酶抑制剂、血浆衍生疗法）、给药途径（静脉注射、皮下、口服）、患者年龄组（儿童、成人、老年人）、诊断类型（获得性遗传性血管性水肿、先天性遗传性血管性水肿、特发性水肿）以及按地区（北美、欧洲、南美、亚太、中东和非洲） - 预测到2035年

- **Forecast Period:** 2025 - 2035
- **CAGR:** 5.71%
- **2024:** $ 2.37 Billion
- **2025:** $ 2.51 Billion
- **2035:** $ 4.38 Billion
- **Key Players:** Shire (GB), CSL Behring (AU), Takeda Pharmaceutical Company Limited (JP), Pharming Group (NL), BioCryst Pharmaceuticals (US), Sobi (SE), Ferring Pharmaceuticals (CH), Vertex Pharmaceuticals (US), Grifols (ES)

**Report ID:** MRFR/HC/35781-HCR · **Pages:** 100 · **Author:** Nidhi Mandole & Rahul Gotadki · **Last Updated:** August 24, 2026

**URL:** https://www.marketresearchfuture.com/reports/hereditary-angioedema-treatment-market-37733

---

## Market Summary

**Hereditary Angioedema Treatment Market Overview**

As per MRFR analysis, the Hereditary Angioedema Treatment Market Size was estimated at 2.37 (USD Billion) in 2024. The Hereditary Angioedema Treatment Market Industry is expected to grow from 2.51 (USD Billion) in 2025 to 4.14 (USD Billion) till 2034, at a CAGR (growth rate) is expected to be around 5.71% during the forecast period (2025 - 2034).

## **Key Hereditary Angioedema Treatment Market Trends Highlighted**

The Hereditary Angioedema Treatment Market is witnessing significant growth driven by a variety of factors. The increasing prevalence of hereditary angioedema, a genetic disorder that leads to recurrent episodes of severe swelling, is a primary market driver. Advances in research and the development of targeted therapies are also contributing to market expansion. Heightened awareness among healthcare professionals and patients has led to more accurate diagnoses and treatment options, reflecting a positive shift in patient management.

Additionally, the rise of telemedicine and digital health solutions enhances patient outreach and ensures better access to treatments.There are several opportunities to be explored in this market. The potential for new treatment modalities, including biologics and gene therapy, presents a frontier for innovation and enhanced patient outcomes.

Expanding geographic reach, particularly in emerging markets where healthcare infrastructure is improving, provides an avenue for growth. Partnerships between pharmaceutical companies and research institutions can accelerate the development of new therapies and enhance clinical trial outcomes.  Recent trends indicate a growing focus on personalized medicine tailored to individual patient needs.

The adoption of new technologies, such as artificial intelligence in drug discovery and patient management systems, is becoming more prevalent.There is also an increasing emphasis on patient education and support programs that empower individuals to manage their condition proactively.

As regulatory frameworks evolve, companies are better positioned to bring their products to market efficiently. Collectively, these factors are shaping a dynamic landscape for the Hereditary Angioedema Treatment Market, paving the way for innovative solutions and improved patient care.

Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review

## **Hereditary Angioedema Treatment Market Drivers**

### Increasing Awareness and Diagnosis of Hereditary Angioedema

The rising awareness and understanding of hereditary angioedema among healthcare professionals and patients significantly contribute to the growth of the Hereditary Angioedema Treatment Market Industry. As more people become knowledgeable about the condition, there is an increased likelihood of seeking diagnosis and treatment. Improved access to information through various channels, including the internet and patient advocacy groups, has facilitated this awareness.

This expanded understanding is driven by numerous factors, including educational campaigns by health organizations and the media's role in highlighting rare diseases such as hereditary angioedema. As a result, patients are more likely to recognize symptoms and seek timely medical intervention. Furthermore, advancements in diagnostic tools and technologies have enabled healthcare providers to more accurately and rapidly identify hereditary angioedema, promoting a proactive approach to treatment.

As diagnoses become more prevalent, the demand for effective therapies and management strategies is expected to rise, further propelling the market forward. The increased diagnosis not only helps in providing timely treatment but also reduces the risk of complications associated with untreated angioedema episodes.

This environment is conducive for pharmaceutical companies to invest in the development and commercialization of innovative treatments.Subsequently, as the population of diagnosed patients grows, the market for hereditary angioedema therapies is poised for substantial expansion, contributing to a significant increase in the market's valuation in the coming years.

### Advancements in Treatment Options

Technological advancements and innovations in treatment options are pivotal drivers in the Hereditary Angioedema Treatment Market Industry. Emerging therapies offer improved efficacy and safety profiles, which are crucial for patients managing this condition. The introduction of modern medications, including targeted therapies, has revolutionized treatment paradigms, allowing for personalized medicine approaches tailored to individual patient needs.

Additionally, the presence of biologics and new classes of drugs is expanding the therapeutic landscape, providing hope for better outcomes in patients suffering from hereditary angioedema. As the research and development efforts continue to yield promising results, the market is likely to witness a surge in new product launches, further stimulating growth.

### Government Initiatives and Support

Government initiatives and regulations supporting research in rare diseases like hereditary angioedema are significant contributors to the growth of the Hereditary Angioedema Treatment Market Industry. Funding for rare disease research, incentives for pharmaceutical companies to develop new therapies, and policy frameworks that encourage innovation create a conducive environment for market growth.

Various governments are recognizing the urgency to address unmet medical needs and are initiating programs aimed at increasing the availability and accessibility of treatment options for hereditary angioedema patients.Such initiatives not only promote investment in research and development but also ensure that patients receive the necessary care and resources to manage their condition effectively.

## **Hereditary Angioedema Treatment Market Segment Insights:**

### **Hereditary Angioedema Treatment Market Type of Treatment Insights  **

The Hereditary Angioedema Treatment Market is characterized by a diverse array of treatment options designed to address the needs of patients suffering from this rare genetic condition. Over the years, the market has shown substantial growth, with an overall valuation of 2.12 USD Billion in 2023. Among the various treatment modalities, C1 Esterase Inhibitor Replacement Therapy stands out as a dominant force, accounting for a significant share of the market with a value of 0.85 USD Billion in 2023 and projected to reach 1.4 USD Billion by 2032.

This therapy is paramount in managing acute attacks and preventing their occurrence, making it crucial for patients and healthcare providers alike.In addition to C1 Esterase Inhibitor Replacement Therapy, other treatment types are also gaining traction. Bradykinin B2 Receptor Antagonists, valued at 0.5 USD Billion in 2023, play an important role by blocking the effects of bradykinin, a peptide that contributes to angioedema.

This option is expected to reach 0.8 USD Billion by 2032, showcasing its growing acceptance within the medical community. On the other hand, Recombinant C1 Esterase Inhibitor, valued at 0.42 USD Billion in 2023, is emerging rapidly as a viable alternative to traditional therapies, presenting a promising option for patients who require tailored treatments, with expectations of increasing to 0.67 USD Billion by 2032.Blood Plasma Derived Therapies also contribute to the treatment landscape, valued at 0.35 USD Billion in 2023 and anticipated to grow to 0.6 USD Billion by 2032.

Although this segment holds the smallest share among the treatment types, it remains essential for patients who may not respond well to other therapies. The interplay of these treatment types underscores the significant dynamics within the Hereditary Angioedema Treatment Market, which reflects current advancements and ongoing research aimed at providing better management solutions.The market is witnessing trends driven by an increase in awareness, the prevalence of hereditary angioedema, and advancements in biotechnology.

There are considerable opportunities for market growth owing to the continuous development of innovative therapies and enhanced patient access to treatments. Challenges persist, however, mostly around the pricing and reimbursement landscape which can affect patient access to necessary therapies. Overall, as the landscape evolves, the Hereditary Angioedema Treatment Market remains well-poised for sustained growth, marked by innovation and an increasing understanding of treatment efficacy and safety.

Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review

### **Hereditary Angioedema Treatment Market Route of Administration Insights  **

The Hereditary Angioedema Treatment Market is projected to be valued at 2.12 USD Billion in 2023, showcasing robust growth in the healthcare sector focused on hereditary conditions. The market segmentation based on Route of Administration plays a crucial role in this expansion, encompassing methods such as [Intravenous](../../../reports/intravenous-solution-market-1235), Subcutaneous, and Oral. Among these, Intravenous administration often leads in preference due to its rapid onset of action, making it essential for acute treatment scenarios where immediate response is critical, thus highlighting its significance in emergency situations.

Subcutaneous administration is growing increasingly popular, providing patients with greater convenience and ease of use, contributing to adherence to treatment protocols. The Oral route is valued for its non-invasive approach, making it a favorable option for long-term management.

The diversity in Route of Administration underlines the importance of tailored treatment approaches, accommodating various patient needs and preferences while driving market growth. As of 2024, the market statistics indicate a steady rise in demand across these routes, suggesting that addressing diverse administration preferences will continue to be a driving factor for the industry.This alignment with patient-centric approaches offers substantial opportunities for innovation and market penetration.

### **Hereditary Angioedema Treatment Market Patient Age Group Insights  **

In 2023, the Hereditary Angioedema Treatment Market is valued at 2.12 USD Billion, reflecting the growing importance of effective treatment options across various age groups. The market segmentation by Patient Age Group reveals distinct dynamics, with Pediatric, Adult, and Geriatric populations all requiring tailored therapeutic approaches. The Pediatric segment is crucial as early diagnosis and intervention can significantly improve health outcomes, making it a vital focus area for treatment strategies.

Adults represent a significant portion of the market, often facing severe symptoms that necessitate ongoing management, thereby driving demand for advanced treatments.The Geriatric age group is also increasingly relevant due to the challenges of managing hereditary angioedema alongside comorbidities, highlighting the need for specialized therapies.

As the Hereditary Angioedema Treatment Market continues to evolve, understanding the unique needs of each age group becomes paramount for stakeholders. The market growth is supported by advancements in medical research, increasing awareness among healthcare providers, and the development of new treatments tailored to these specific demographics, which collectively enhance the Hereditary Angioedema Treatment Market revenue and statistics.

### **Hereditary Angioedema Treatment Market Diagnosis Type Insights  **

The Hereditary Angioedema Treatment Market, focusing on the Diagnosis Type segment, has portrayed a robust landscape with significant value attributed to its various categories. In 2023, the overall market was valued at approximately 2.12 billion USD, reflecting the increasing awareness and diagnosis of hereditary angioedema disorders. Among the different types, Congenital Hereditary Angioedema is notably prominent, as it is a genetic condition requiring ongoing management, thereby bolstering the market growth.

Moreover, Acquired Hereditary Angioedema has gained attention due to its varied etiology and potential underlying conditions, contributing to a substantial share in the market.Moreover, Idiopathic Angioedema has emerged as a significant concern, presenting challenges in diagnosis and treatment, which are driving further research and development initiatives.

The increasing prevalence of these conditions and advancements in diagnostic technologies are acting as primary growth drivers, alongside the ongoing demand for effective therapeutic solutions. Nevertheless, challenges such as diagnosis complexities and limited awareness in some regions may hinder market expansion. Overall, the Hereditary Angioedema Treatment Market data illustrates a favorable trend, supported by a constant need for improved treatment strategies across these diagnosis types.

### **Hereditary Angioedema Treatment Market Regional Insights  **

The Hereditary Angioedema Treatment Market is showing notable regional variances in market valuation and dynamics. In 2023, North America led the market with a valuation of 1.08 USD Billion, expected to grow to 1.85 USD Billion by 2032, underscoring its majority holding within the industry. Europe follows, with a market value of 0.75 USD Billion in 2023, predicted to reach 1.2 USD Billion in 2032, indicating its significant role in the treatment landscape.

The APAC region, while currently valued at 0.23 USD Billion, is anticipated to expand to 0.45 USD Billion, reflecting a growing awareness and treatment adoption in hereditary angioedema.South America and MEA represent the smaller segments of the market, valued at 0.03 USD Billion each in 2023, with minor increases expected. Despite their lower market figures of 0.07 USD Billion and 0.05 USD Billion in 2032 respectively, they present opportunities for growth as healthcare infrastructure develops.

The variation in market size across these regions reflects disparities in healthcare access, industry growth, and treatment availability, thus impacting the Hereditary Angioedema Treatment Market data and statistics across different geographical landscapes.

Source: Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review

### **Hereditary Angioedema Treatment Market Key Players and Competitive Insights:**

The Hereditary Angioedema Treatment Market is witnessing significant competitive dynamics as key players strive to offer effective solutions for managing this rare genetic condition characterized by recurrent episodes of swelling. The market landscape has been shaped by the increasing prevalence of hereditary angioedema, heightened awareness among healthcare professionals, and advancements in treatment options. Companies are focusing on innovative therapies, including prophylactic treatments and on-demand therapies, to enhance patient outcomes.

The emergence of novel biologics and targeted therapies is revolutionizing treatment paradigms, leading to stiff competition among established and emerging players. Furthermore, collaborations, partnerships, and strategic alliances are becoming more prevalent as organizations seek to tap into complementary capabilities to bolster their market positioning.

Ionis Pharmaceuticals is recognized for its robust pipeline focused on RNA-targeted therapeutic modalities, which has allowed it to establish a formidable presence in the Hereditary Angioedema Treatment Market.

The company leverages its expertise in antisense technology to develop therapies aimed at addressing the underlying genetic causes of hereditary angioedema. One of the key strengths of Ionis Pharmaceuticals lies in its ability to target specific molecular pathways associated with the disease, resulting in potentially groundbreaking treatment options that could offer significant benefits to patients. Furthermore, its commitment to research and development ensures a continuous flow of innovative products, enhancing its competitive edge in a market that demands effective and safe therapeutic alternatives.

The company’s reputation for scientific excellence and its strategic focus on unmet medical needs further bolster its standing within the industry.Pfizer has carved out a strong niche within the Hereditary Angioedema Treatment Market, driven by its dedication to improving patient care through effective therapeutic solutions.

The company’s wide-ranging portfolio and extensive experience in the biotechnology sector give it a competitive advantage, enabling it to offer comprehensive treatment options for hereditary angioedema. Pfizer's commitment to research and development is reflected in its robust clinical pipeline, which aims to deliver innovative therapies targeting various manifestations of the disease.

Additionally, its established relationships with healthcare providers and payers enhance access to its products, ensuring broader market penetration. Pfizer’s reputation for quality and reliability, combined with its agile approach to market needs, positions it favorably against competitors, allowing for sustained growth and influence within this specialized therapeutic landscape.

### **Key Companies in the Hereditary Angioedema Treatment Market Include:**

- Ionis Pharmaceuticals
- Pfizer
- H Genzyme
- Revance Therapeutics
- Eurordis
- Baxter
- Sobi
- Portola Pharmaceuticals
- **[Amgen](https://www.amgen.com/products)**
- Biocryst Pharmaceuticals
- ViroPharma
- Takeda
- CSL Behring
- Shire
- Sanofi

### Hereditary Angioedema Treatment Industry Developments

- **Q2 2025: World Hereditary Angioedema Day: New drug approvals expand treatment options** In May 2025, garadacimab, a new long-term prophylactic treatment for hereditary angioedema, became available in Austria, allowing patients to self-administer the drug using a pen. The approval of donidalorsen as another treatment option is expected in the coming months, further expanding choices for patients who have not responded to previous therapies.

## **Hereditary Angioedema Treatment Market Segmentation Insights**

### **Hereditary Angioedema Treatment Market Type of Treatment Outlook**

- C1 Esterase Inhibitor Replacement Therapy
- Bradykinin B2 Receptor Antagonists
- Recombinant C1 Esterase Inhibitor
- Blood Plasma Derived Therapies

### **Hereditary Angioedema Treatment Market Route of Administration Outlook**

- Intravenous
- Subcutaneous
- Oral

### **Hereditary Angioedema Treatment Market Patient Age Group Outlook**

- Pediatric
- Adult
- Geriatric

### **Hereditary Angioedema Treatment Market Diagnosis Type Outlook**

- Acquired Hereditary Angioedema
- Congenital Hereditary Angioedema
- Idiopathic Angioedema

### **Hereditary Angioedema Treatment Market Regional Outlook**

- North America
- Europe
- South America
- Asia Pacific
- Middle East and Africa

## Market Drivers

### 治疗选择的进展

遗传性血管性水肿治疗市场受到治疗选择进展的显著影响。最近的创新，包括靶向疗法和生物制剂的引入，已经改变了HAE的管理。这些新疗法不仅改善了患者的结果，还减少了发作的频率和严重性。例如，C1抑制剂疗法和布拉迪激肽受体拮抗剂的批准为患者提供了更有效的管理策略。随着这些新疗法在医疗提供者和患者中获得认可，市场预计将增长。此外，正在进行的临床试验和研究计划可能会带来进一步的进展，从而增强遗传性血管性水肿治疗市场的治疗格局。

### 创新疗法的监管支持

创新疗法的监管支持是遗传性血管性水肿治疗市场的重要驱动力。监管机构越来越认识到需要为满足未满足的医疗需求的新疗法提供加速审批流程。这一趋势在遗传性血管性水肿（HAE）中尤为相关，及时获得有效疗法可以显著改善患者的生活质量。实施孤儿药物指定和快速通道审批等项目可能会鼓励制药公司投资于HAE治疗。因此，遗传性血管性水肿治疗市场有望增长，源源不断的新疗法能够满足患者不断变化的需求。

### 发展患者倡导和支持团体

患者倡导和支持团体的存在在遗传性血管性水肿治疗市场中发挥着关键作用。这些组织在提高对遗传性血管性水肿（HAE）的认识、教育患者和医疗提供者以及倡导更好的治疗选择方面发挥着重要作用。他们的努力有助于提高诊断率，并鼓励患者寻求适当的护理。此外，这些团体通常与制药公司合作，促进临床试验并收集患者反馈，这可能会影响新疗法的开发。随着这些倡导团体的影响力不断扩大，遗传性血管性水肿治疗市场可能会看到对有效治疗方案的需求相应增加。

### 增加对研究和开发的投资

对遗传性血管性水肿治疗市场的研究与开发（R&D）投资是一个关键驱动因素。制药公司正在分配大量资源来开发新疗法并改善现有疗法。这一趋势在市场上表现得尤为明显，临床试验的激增旨在探索创新的治疗方式。对研发的财务承诺预计将带来突破，这可能会显著改变HAE的治疗范式。此外，学术机构与行业参与者之间的合作正在促进一个有利于创新的环境。因此，遗传性血管性水肿治疗市场可能会受益于不断涌现的新疗法，从而提升患者护理和治疗效果。

### 遗传性血管神经性水肿发病率上升

遗传性血管性水肿治疗市场正在增长，原因是遗传性血管性水肿（HAE）病例的发生率上升。最近的估计表明，HAE大约影响每1万人到5万人中的1人，这导致对有效治疗方案的需求增加。随着对这种疾病的认识提高，越来越多的患者被诊断出来，这反过来又推动了对创新疗法的需求。HAE的日益普遍促使医疗服务提供者寻求先进的治疗方式，从而扩大了市场。此外，针对特定患者需求开发的新疗法可能会改善治疗效果，进一步促进遗传性血管性水肿治疗市场的整体增长。

## Future Outlook

遗传性血管性水肿治疗市场预计将在2024年至2035年间以5.71%的年均增长率增长，推动因素包括治疗方法的进步、意识的提高和诊断方法的改善。

**New opportunities:**

- 利用基因分析制定个性化治疗方案。

到2035年，市场预计将实现显著增长，反映出不断发展的治疗范式和患者获取的增加。

## Segment Insights

### 按类型：C1 酯酶抑制剂替代疗法（最大）与缓激肽 B2 受体拮抗剂（增长最快）

遗传性血管性水肿治疗市场显示出多样的细分，其中C1酯酶抑制剂替代疗法占据最大份额。这个以其在治疗急性发作中的有效性而闻名的成熟细分市场，显著影响着市场动态。同时，虽然布拉迪激肽B2受体拮抗剂的市场份额较小，但其展现出令人印象深刻的增长，吸引了越来越多寻求创新治疗方案的积极患者人群。

C1 酯酶抑制剂替代疗法（显性）与布拉迪激肽 B2 受体拮抗剂（新兴）

C1 酯酶抑制剂替代疗法是一种成熟的治疗方法，是遗传性血管性水肿患者治疗的基础。其主导地位归因于其在快速缓解发作方面的有效性。另一方面，布拉迪激肽 B2 受体拮抗剂代表了一种新兴的治疗选择，因其新颖的作用机制而受到关注。随着市场的发展，这些拮抗剂越来越被视为综合治疗策略的一部分，因其有潜力预防发作而不仅仅是治疗发作而受到关注。

### 按给药途径：皮下（最大）与静脉注射（增长最快）

在遗传性血管性水肿治疗市场中，给药途径在治疗效果和患者依从性方面起着至关重要的作用。目前，皮下给药途径因其对患者友好的特性而主导市场，允许自我给药并减少住院就诊的需求。这一途径在患者中获得了显著的关注，导致市场份额稳步增长。相反，静脉给药途径虽然不太方便，但在需要在急性发作期间立即获得治疗效果的患者中，正迅速引起关注。

静脉注射：增长最快 vs. 皮下注射：主导

静脉给药途径是遗传性血管性水肿治疗市场中增长最快的细分领域，主要是由于其在控制急性发作方面的有效性。在临床环境中，尤其是对于那些有严重表现的患者，静脉给药被优先选择以获得即时缓解。另一方面，皮下给药仍然是主导方法，因其便利性和易用性而受到青睐，使患者能够在家中有效管理他们的病情。这种给药方式大大提高了治疗方案的依从性，吸引了更大的人群。随着市场的发展，这两个细分领域之间的相互作用将塑造治疗策略和患者偏好。

### 按患者年龄组：成人（最大）与儿童（增长最快）

遗传性血管性水肿治疗市场在各个患者年龄组中展现出多样化的分布。其中，成人群体占据了最大的市场份额，主要是由于遗传性血管性水肿在成人中的发病率高于儿童或老年人群体。该细分市场受益于一系列专门针对成人患者的治疗选择，从而巩固了其主导地位。

相比之下，儿童细分市场正在成为遗传性血管性水肿治疗市场中增长最快的细分市场。多个因素促成了这一趋势，包括医疗专业人员和家长对遗传性血管性水肿的认识不断提高，导致更早的诊断。此外，儿童治疗选择的进步也推动了增长，使市场利益相关者必须专注于为年轻患者开发量身定制的疗法，因为他们在发病率和重要性上不断增长。

成人（主导）与儿童（新兴）

遗传性血管性水肿治疗市场的成人细分市场以其广泛的可用治疗方案和对持续管理与该病症相关的症状的显著需求为特征。成人通常经历更严重和更频繁的发作，这需要强有力的干预策略。该细分市场的提供者专注于已建立的疗法，包括C1抑制剂制剂和在成人群体中显示出疗效的新型生物制剂。相比之下，儿童细分市场作为一个新兴的关注领域正在获得关注，这得益于发病率的上升和针对儿童的特定疗法的不断增加。儿童患者面临不同的挑战，包括对更安全和更易耐受的制剂的需求，这使得市场对针对这一脆弱人群的创新解决方案充满期待。

### 按诊断类型：先天性遗传性血管神经性水肿（最大）与获得性遗传性血管神经性水肿（增长最快）

在遗传性血管性水肿治疗市场中，先天性遗传性血管性水肿（HAE）作为最大的细分市场，因其遗传特性和在受影响人群中的较高发病率而脱颖而出。虽然获得性遗传性血管性水肿的市场较小，但由于对其因潜在疾病或药物引起的发病率的日益认识，正受到越来越多的关注，这导致了治疗方案的转变。这两个细分市场共同反映了HAE类型的复杂性及其对治疗策略的影响。

先天性遗传性血管神经性水肿（显性）与获得性遗传性血管神经性水肿（新兴）

先天性遗传性水肿（HAE）在市场上占据主导地位，因为这是一种通常在生命早期出现的遗传性疾病，导致对长期治疗选择的需求更为显著。该细分市场的特点是对其遗传机制有着良好的理解，这推动了靶向疗法的发展。另一方面，获得性遗传性水肿是一个新兴细分市场，归因于其与各种疾病的关联以及快速变化的治疗格局。随着对该病症表现和诱因的认识不断提高，创新疗法的需求也在增加，进一步刺激了市场动态。这些对比突显了HAE治疗领域利益相关者的多样化机会。

## Regional Market Share Analysis

### 北美：治疗的领先市场

北美是遗传性血管性水肿（HAE）治疗的最大市场，占全球市场份额的约60%。该地区的增长受到意识提升、治疗选择的进步和支持性监管框架的推动。美国在这一市场中处于领先地位，其次是加拿大，加拿大对创新疗法和患者支持项目的需求贡献显著。北美的竞争格局强劲，主要参与者包括Shire、BioCryst制药和Vertex制药。这些公司积极参与研究和开发，旨在提高治疗效果和患者结果。成熟的医疗基础设施和有利的报销政策进一步促进了市场增长，使其成为HAE治疗进展的焦点。

### 欧洲：新兴市场动态

欧洲在遗传性血管性水肿治疗市场中正经历显著增长，约占全球市场份额的25%。该地区受益于完善的医疗系统、日益增强的患者意识和支持性法规。德国和法国等国处于前沿，通过创新治疗选择和患者倡导举措推动需求。监管机构也在改善对疗法的获取，这预计将进一步刺激市场增长。欧洲的主要国家包括德国、法国和英国，主要参与者如CSL Behring和Pharming Group积极参与。竞争格局以合作和伙伴关系为特征，旨在改善治疗的可及性和患者结果。先进的医疗设施和正在进行的临床试验为市场环境的动态性做出了贡献，促进了HAE疗法的创新。

### 亚太地区：治疗的新兴强国

亚太地区正在成为遗传性血管性水肿治疗市场的重要参与者，目前占全球市场份额的约10%。该地区的增长受到医疗支出增加、对HAE的认识提升和新疗法引入的推动。日本和澳大利亚等国正在引领潮流，越来越多的患者寻求有效的治疗选择和改善的医疗服务。亚太地区的竞争格局正在演变，主要参与者如武田制药和Sobi正在扩大其市场份额。该地区正在经历临床试验和研究计划的涌入，旨在增强治疗选择。此外，政府对罕见疾病管理的支持为HAE疗法的市场渗透和创新铺平了道路，使其成为未来增长的有希望领域。

### 中东和非洲：未开发的市场机会

中东和非洲地区目前是遗传性血管性水肿治疗的最小市场，占全球市场份额的约5%。然而，随着医疗投资的增加、对罕见疾病认识的提升以及对有效治疗选择的需求，增长潜力巨大。南非和阿联酋等国开始认识到HAE管理的重要性，这预计将催化市场发展。竞争格局仍在发展中，主要全球参与者的存在有限。然而，当地制药公司开始参与合作与伙伴关系，以增强治疗的可用性。该地区的医疗系统正在逐步改善，政府针对罕见疾病管理的举措可能会为HAE治疗创造新的机会，使其成为未来投资的关注领域。

## Competitive Benchmarking

遗传性血管性水肿治疗市场的特点是动态的竞争格局，受到对该病症认识的提高和治疗选择的进步的推动。主要参与者如武田制药公司（日本）、BioCryst制药（美国）和CSL Behring（澳大利亚）处于前沿，各自采取不同的策略来增强其市场存在感。武田（日本）专注于通过开发新疗法来推动创新，而BioCryst（美国）则强调战略合作伙伴关系以扩展其产品供应。CSL Behring（澳大利亚）利用其全球影响力来优化分销渠道，从而提高其治疗的可及性。这些策略共同促成了一个日益关注以患者为中心的解决方案和创新治疗方式的竞争环境。

在商业策略方面，各公司越来越多地本地化制造并优化供应链管理以提高效率并降低成本。市场似乎适度分散，多个参与者争夺市场份额。然而，大公司的影响力是显著的，因为它们为创新设定了步伐，并为治疗选择的质量和有效性建立了基准。这种竞争结构促成了一个环境，在这个环境中，较小的公司可能难以竞争，除非它们开辟利基市场或形成战略联盟。

2025年8月，BioCryst制药（美国）宣布与一家领先的生物技术公司合作，共同开发一种新的口服遗传性血管性水肿疗法。这一合作在战略上具有重要意义，因为它不仅使BioCryst的产品组合多样化，还增强了其研究能力，可能加速新治疗的开发时间表。这种合作表明了一种更广泛的趋势，即公司寻求汇聚资源和专业知识，以更有效地应对药物开发的复杂性。

2025年9月，武田制药公司（日本）推出了一项新的患者支持计划，旨在改善遗传性血管性水肿患者的治疗依从性。这一举措强调了武田对患者参与和教育的承诺，这些因素越来越被认为是成功治疗结果的关键组成部分。通过营造一个支持性环境，武田可能会增强患者忠诚度并改善整体市场定位。

2025年10月，CSL Behring（澳大利亚）在欧洲扩大了其制造能力，以更好地满足对其遗传性血管性水肿治疗日益增长的需求。这一战略举措不仅使CSL Behring能够更迅速地响应市场需求，还反映了其通过本地化生产对可持续性的承诺。这种扩张可能会增强供应链的可靠性，这是在制药行业保持竞争优势的关键因素。

截至2025年10月，遗传性血管性水肿治疗市场的竞争趋势越来越受到数字化、可持续性和人工智能在药物开发过程中的整合的定义。战略联盟变得越来越普遍，使公司能够利用共享的专业知识和资源。展望未来，竞争差异化预计将演变，明显从基于价格的竞争转向创新、技术进步和强大的供应链管理。这一转变可能最终重新定义公司在市场中的定位，强调质量和有效性的重要性，而不仅仅是成本。

## Recent News & Developments

- **2025年第二季度：世界遗传性血管性水肿日：新药批准扩展治疗选择** 2025年5月，garadacimab作为一种新的长期预防性治疗遗传性血管性水肿的药物在奥地利上市，患者可以使用笔自我注射该药物。预计在未来几个月内，donidalorsen作为另一种治疗选择的批准将进一步扩展未对先前疗法产生反应的患者的选择。

## Report Scope

| 2024年市场规模 | 2.374（十亿美元） |
| --- | --- |
| 2025年市场规模 | 2.51（十亿美元） |
| 2035年市场规模 | 4.375（十亿美元） |
| 复合年增长率（CAGR） | 5.71%（2024 - 2035） |
| 报告覆盖范围 | 收入预测、竞争格局、增长因素和趋势 |
| 基准年 | 2024 |
| 市场预测期 | 2025 - 2035 |
| 历史数据 | 2019 - 2024 |
| 市场预测单位 | 十亿美元 |
| 主要公司简介 | 市场分析进行中 |
| 覆盖的细分市场 | 市场细分分析进行中 |
| 主要市场机会 | 生物制剂和基因治疗的进展为遗传性血管水肿治疗市场提供了新的机会。 |
| 主要市场动态 | 对新疗法的需求上升推动了遗传性血管水肿治疗市场的竞争创新。 |
| 覆盖的国家 | 北美、欧洲、亚太、南美、中东和非洲 |

## Frequently Asked Questions

**Q: 2035年遗传性血管性水肿治疗市场的预计市场估值是多少？**
A: 预计到2035年，遗传性血管性水肿治疗市场的市场估值将达到43.75亿美元。

**Q: 2024年遗传性血管性水肿治疗市场的市场估值是多少？**
A: 2024年遗传性血管性水肿治疗市场的市场估值为23.74亿美元。

**Q: 2025年至2035年遗传性血管性水肿治疗市场的预期CAGR是多少？**
A: 在2025年至2035年的预测期内，遗传性血管性水肿治疗市场的预期CAGR为5.71%。

**Q: 在遗传性血管性水肿治疗市场中，哪些公司被视为关键参与者？**
A: 遗传性血管性水肿治疗市场的主要参与者包括Shire、CSL Behring、武田药品工业有限公司等。

**Q: 2024年，遗传性血管水肿治疗市场哪个细分领域的估值最高？**
A: 在2024年，C1酯酶抑制剂替代疗法的细分市场估值最高，达到9.5亿美元。

**Q: 2024年口服给药的市场估值与其他给药途径相比如何？**
A: 在2024年，口服给药的市场估值为9.5亿美元，高于静脉注射和皮下给药途径。

**Q: 2024年儿科年龄段市场估值是多少？**
A: 2024年儿科年龄组细分市场的估值为4.74亿美元。

**Q: 到2035年，先天性遗传性血管性水肿诊断类型的预计增长是多少？**
A: 预计到2035年，先天性遗传性血管水肿诊断类型的增长将达到21.25亿美元。

**Q: 到2035年，预计哪种给药途径将显示显著增长？**
A: 静脉注射和皮下给药途径预计将显著增长，估值预计到2035年将达到13.25亿美元。

**Q: 2024年血浆衍生疗法的市场估值是多少？**
A: 2024年血浆衍生疗法的市场估值为3亿美元。


---

*This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/hereditary-angioedema-treatment-market-37733*